Survival after second-line therapy in patients with metastatic kidney cancer treated with first-line immunotherapy combinations
This study looked at real world information from patients with [...]
Nivolumab plus ipilimumab for advanced kidney cancer after progression on immunotherapy
This phase 2 study looked at the effect on survival [...]
CAR T-cell therapy shows promise in kidney cancer
A recent study looking at a CAR T-cell therapy (called [...]
Side effect management for kidney cancer treatments
At the International Kidney Cancer Symposium (IKCS) in the USA [...]
Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
Adjuvant pembrolizumab approved in Scotland
Yesterday is was announced that the Scottish Medicines Consortium (SMC) [...]
A modified nivolumab/ipilimumab dosing regimen
In this phase 3b/4 study, people with advanced kidney cancer [...]
C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer
A biomarker is a biological molecule found in blood, other body [...]
Adjuvant pembrolizumab approved by NICE
Late last week we learnt that the National Institute for [...]
Telaglenastat plus cabozantinib in patients with metastatic kidney cancer
Cell metabolism in kidney cancer tumours is disrupted, and tumour [...]
